TY - JOUR
T1 - Can Treg therapy prevent GVHD?
AU - Komanduri, Krishna V.
AU - Champlin, Richard E.
PY - 2011/1/20
Y1 - 2011/1/20
N2 - In this issue of Blood, Brunstein and colleagues report the results of the first study to test the safety of human umbilical cord blood - derived regulatory T cells (Tregs), an approach designed to decrease graft-versus-host disease.1 Transplanters, like Sisyphus of myth, have struggled mightily with trials of pharmacologic immunosuppressive drugs - we roll the rock up the mountain, only to see it roll back, leaving us where we began. This struggle has now led us to seek cellular therapies as a promising alternative.
AB - In this issue of Blood, Brunstein and colleagues report the results of the first study to test the safety of human umbilical cord blood - derived regulatory T cells (Tregs), an approach designed to decrease graft-versus-host disease.1 Transplanters, like Sisyphus of myth, have struggled mightily with trials of pharmacologic immunosuppressive drugs - we roll the rock up the mountain, only to see it roll back, leaving us where we began. This struggle has now led us to seek cellular therapies as a promising alternative.
UR - http://www.scopus.com/inward/record.url?scp=78751691629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751691629&partnerID=8YFLogxK
U2 - 10.1182/blood-2010-11-317305
DO - 10.1182/blood-2010-11-317305
M3 - Comment/debate
C2 - 21252098
AN - SCOPUS:78751691629
SN - 0006-4971
VL - 117
SP - 751
EP - 752
JO - Blood
JF - Blood
IS - 3
ER -